Review





Similar Products

94
Guangzhou JET Bio-Filtration mouse il-1β (interleukin 1 beta) elisa kit
Mouse Il 1β (Interleukin 1 Beta) Elisa Kit, supplied by Guangzhou JET Bio-Filtration, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse il-1β (interleukin 1 beta) elisa kit/product/Guangzhou JET Bio-Filtration
Average 94 stars, based on 1 article reviews
mouse il-1β (interleukin 1 beta) elisa kit - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

96
R&D Systems mouse il 10 elisa kit
circSMAD4 drives tumor-educated M2-like polarization of macrophages and promotes tumor-cell aggressiveness. (A) Workflow for generating TC-hMDMs and TC-BMDMs, circSMAD4 knockdown, and downstream functional assays. (B) RT–qPCR analysis of M1-associated markers (MHC-II [HLA-DRA in TC-hMDMs; H2-Ab1 in TC-BMDMs], NOS2, and CD86) and M2-associated markers (CD163, CD206, and ARG1) in TC-hMDMs and TC-BMDMs. (C) Representative flow-cytometry histograms for HLA-DR, iNOS, CD86, CD163, CD206, and ARG1 in TC-hMDMs. Gating strategy and marker thresholds were defined based on FMO controls (see ). (D) Flow-cytometry quantification of marker-positive cells in TC-hMDMs and TC-BMDMs. (E) ELISA of <t>IL-10,</t> TGF-β, and iNOS in culture supernatants. (F) CCK-8 assays of A549 and LLC cells. (G) Colony-formation assays of A549 and LLC cells with quantification. (H) Bioluminescence-based growth readouts of patient-derived LUAD organoids (PDO #1 and PDO #2) after co-culture with TC-hMDMs. (I) Immunoblot analysis of EMT-related proteins (E-cadherin, N-cadherin, Vimentin) in A549 and LLC cells. (J) Transwell migration and invasion assays of A549 and LLC cells with quantification. Scale bar, 50 μm. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001; ns, not significant.
Mouse Il 10 Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse il 10 elisa kit/product/R&D Systems
Average 96 stars, based on 1 article reviews
mouse il 10 elisa kit - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

93
Boster Bio il 10 specific antibodies
Angiogenesis and collagen deposition in diabetic wound tissues following HPSL@SG hydrogel treatment. (A) Dihydroethidium (DHE) immunofluorescence staining and (B) semi-quantitative analysis of wound tissues from each treatment group on day 7, scale bar = 100 μm. Immunofluorescence staining of (C) MMP-9, IL-6, and <t>IL-10,</t> and (D) CD31, VEGF-A, and collagen I in wound tissue sections from each treatment group on day 7, scale bar = 100 μm. (E-J) Mean relative fluorescence intensity of each indicator in wound tissue sections from each treatment group on day 7, scale bar = 100 μm. All data are shown as mean ± SEM (n = 6).
Il 10 Specific Antibodies, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il 10 specific antibodies/product/Boster Bio
Average 93 stars, based on 1 article reviews
il 10 specific antibodies - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

93
Boster Bio il 10
Elevated PD-1 expression and altered cytokine levels in plasma of IE patients. (A) PD-1 expression on CD4 + CD25 high Tregs is significantly increased in IE patients, particularly in the ISE subgroup, while CD4 + and CD4 + CD25 + T cell percentages are reduced. (B) Plasma concentrations <t>of</t> <t>IL-10</t> and IL-6 are elevated in IE patients, with IL-10 showing a progressive increase with seizure severity. (C) Correlation analyses reveal associations between immune parameters and clinical characteristics. ∗∗∗P < 0.001, ∗∗ P < 0.01, ∗ P < 0.05; ns indicates not significant.
Il 10, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il 10/product/Boster Bio
Average 93 stars, based on 1 article reviews
il 10 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

97
Elabscience Biotechnology e el m0037
Elevated PD-1 expression and altered cytokine levels in plasma of IE patients. (A) PD-1 expression on CD4 + CD25 high Tregs is significantly increased in IE patients, particularly in the ISE subgroup, while CD4 + and CD4 + CD25 + T cell percentages are reduced. (B) Plasma concentrations <t>of</t> <t>IL-10</t> and IL-6 are elevated in IE patients, with IL-10 showing a progressive increase with seizure severity. (C) Correlation analyses reveal associations between immune parameters and clinical characteristics. ∗∗∗P < 0.001, ∗∗ P < 0.01, ∗ P < 0.05; ns indicates not significant.
E El M0037, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/e el m0037/product/Elabscience Biotechnology
Average 97 stars, based on 1 article reviews
e el m0037 - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier

94
Elabscience Biotechnology e el m0725
Elevated PD-1 expression and altered cytokine levels in plasma of IE patients. (A) PD-1 expression on CD4 + CD25 high Tregs is significantly increased in IE patients, particularly in the ISE subgroup, while CD4 + and CD4 + CD25 + T cell percentages are reduced. (B) Plasma concentrations <t>of</t> <t>IL-10</t> and IL-6 are elevated in IE patients, with IL-10 showing a progressive increase with seizure severity. (C) Correlation analyses reveal associations between immune parameters and clinical characteristics. ∗∗∗P < 0.001, ∗∗ P < 0.01, ∗ P < 0.05; ns indicates not significant.
E El M0725, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/e el m0725/product/Elabscience Biotechnology
Average 94 stars, based on 1 article reviews
e el m0725 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

86
Wuhan Fine Biotech mouse t testosterone elisa kit
Genomic instability is observed in InCl 3 -treated TM3 cells. InCl 3 induces enlarged nuclei and micronuclei (as indicated by white arrowheads) in TM3 cells. (A) Nuclear shapes of CTL and InCl 3 -treated TM3 cells were analyzed using DAPI staining. The right panel represents enlarged views of selected regions. Micronuclei, small DAPI staining near the nucleus, are indicated by the arrowheads. Mitotic cells were identified and are marked with red circles. Scale bar, 10 µm. (B) Quantitative results of the nuclear area shown through DAPI staining. (C) Quantification of the proportions of cells with micronuclei [as indicated by selected regions 1 and 2 of (A), right panel]. (D) InCl 3 treatment did not affect the mitotic index. The proportions of mitotic cells (mitotic index) were quantified. (E) InCl 3 treatment reduced the levels of <t>testosterone</t> in the culture medium of TM3 cells. Quantitative results of relative testosterone levels measured through <t>ELISA</t> in the absence or presence of InCl 3 . InCl 3 treatment reduced steroidogenic gene expression. (F) Schematic diagram of testosterone production. Quantitative results of relative mRNA levels of (G) StAR, (H) HSD3B and (I) CYP11A1. Results are presented as mean ± SD from ≥3 independent experiments. *P<0.05, **P<0.01 and ***P<0.001. n.s., not significant; InCl 3 , indium chloride; StAR, steroidogenic acute regulatory protein; HSD3B, 3-β-hydroxy-δ-steroid dehydrogenase; CYP11A1, cytochrome P450 family 11 subfamily A member 1; E, enlarged nuclei; CTL, control.
Mouse T Testosterone Elisa Kit, supplied by Wuhan Fine Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse t testosterone elisa kit/product/Wuhan Fine Biotech
Average 86 stars, based on 1 article reviews
mouse t testosterone elisa kit - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

96
Elabscience Biotechnology tnf alpha
Genomic instability is observed in InCl 3 -treated TM3 cells. InCl 3 induces enlarged nuclei and micronuclei (as indicated by white arrowheads) in TM3 cells. (A) Nuclear shapes of CTL and InCl 3 -treated TM3 cells were analyzed using DAPI staining. The right panel represents enlarged views of selected regions. Micronuclei, small DAPI staining near the nucleus, are indicated by the arrowheads. Mitotic cells were identified and are marked with red circles. Scale bar, 10 µm. (B) Quantitative results of the nuclear area shown through DAPI staining. (C) Quantification of the proportions of cells with micronuclei [as indicated by selected regions 1 and 2 of (A), right panel]. (D) InCl 3 treatment did not affect the mitotic index. The proportions of mitotic cells (mitotic index) were quantified. (E) InCl 3 treatment reduced the levels of <t>testosterone</t> in the culture medium of TM3 cells. Quantitative results of relative testosterone levels measured through <t>ELISA</t> in the absence or presence of InCl 3 . InCl 3 treatment reduced steroidogenic gene expression. (F) Schematic diagram of testosterone production. Quantitative results of relative mRNA levels of (G) StAR, (H) HSD3B and (I) CYP11A1. Results are presented as mean ± SD from ≥3 independent experiments. *P<0.05, **P<0.01 and ***P<0.001. n.s., not significant; InCl 3 , indium chloride; StAR, steroidogenic acute regulatory protein; HSD3B, 3-β-hydroxy-δ-steroid dehydrogenase; CYP11A1, cytochrome P450 family 11 subfamily A member 1; E, enlarged nuclei; CTL, control.
Tnf Alpha, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tnf alpha/product/Elabscience Biotechnology
Average 96 stars, based on 1 article reviews
tnf alpha - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

94
Novus Biologicals osteogenic marker osteocalcin
Continuous intraosseous administration of SCS prevents glucocorticoid-induced bone degeneration. ( A ) Schematic illustration of the glucocorticoid (GC; MPS)-induced bone deterioration and intraosseous SCS treatment. ( B-D ) Representative H&E staining images of the femur at 6 weeks (B). Magnified views of the cortical bone and trabecular bone in the marrow cavity are shown on the right. Solid arrows indicate normal osteocytes, while hollow arrows indicate empty osteocyte lacunae. Quantification of empty lacunae ratios in cortical bone (C) and trabecular bone (D). n = 6 biological replicates. (Scale bars, 500 μm and 25 μm) ( E-H ) Representative immunofluorescence staining of OPN + mature osteoblasts, osteolectin + osteoprogenitors, and VE-cadherin + endothelial cells (ECs) in femur at 6 weeks (E), and corresponding quantifications (F–H). n = 6 biological replicates. (Scale bars, 100 μm and 20 μm) ( I and J ) Representative flow cytometry plots of capillary subtypes in the femur (I), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (J). n = 6 biological replicates. ( K and L ) Flow cytometry plots showing Sca-1 hi CD31 hi arteriolar ECs (K), and corresponding quantification (L). n = 6 biological replicates. ( M and N ) Representative micro-CT 3D images of the femur (M). Quantitative analysis of percent bone volume (BV/TV) (N). n = 6 biological replicates. (Scale bars, 1.5 mm, 600 μm and 545 μm) ( O and P ) ELISA analysis of VEGF (O) and PDGF-BB (P) levels in bone marrow supernatant and peripheral serum from PBS- and SCS-treated groups at week 6. n = 6 biological replicates. ( Q ) ELISA quantification of the <t>osteogenic</t> factor <t>osteocalcin</t> in peripheral serum at week 6. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, F, G, H, J, L, N, O, P and Q ).
Osteogenic Marker Osteocalcin, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/osteogenic marker osteocalcin/product/Novus Biologicals
Average 94 stars, based on 1 article reviews
osteogenic marker osteocalcin - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

97
R&D Systems il 13
Effects of CuONPs on allergic inflammation and oxidative stress in OVA-induced asthmatic mice. (A) Airway hyperresponsiveness assessed as total respiratory system resistance in response to methacholine challenge (10, 20, and 40 mg/mL). (B–F) Total and differential inflammatory cell counts in BALF. (G–L) IL-1β, IL-6, TNF-α, IL-4, IL-5, <t>and</t> <t>IL-13</t> levels in BALF, measured by ELISA. (M and N) Total IgE and OVA specific IgE levels in serum. (O and P) MDA levels and SOD activity in lung tissue. Data are presented as means ± SD (n = 6 mice/group). ∗∗ p < 0.01 and ∗∗∗ p < 0.001 versus NC group. # p < 0.05, ## p < 0.01, and ### p < 0.001 versus OVA group.
Il 13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il 13/product/R&D Systems
Average 97 stars, based on 1 article reviews
il 13 - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier

Image Search Results


circSMAD4 drives tumor-educated M2-like polarization of macrophages and promotes tumor-cell aggressiveness. (A) Workflow for generating TC-hMDMs and TC-BMDMs, circSMAD4 knockdown, and downstream functional assays. (B) RT–qPCR analysis of M1-associated markers (MHC-II [HLA-DRA in TC-hMDMs; H2-Ab1 in TC-BMDMs], NOS2, and CD86) and M2-associated markers (CD163, CD206, and ARG1) in TC-hMDMs and TC-BMDMs. (C) Representative flow-cytometry histograms for HLA-DR, iNOS, CD86, CD163, CD206, and ARG1 in TC-hMDMs. Gating strategy and marker thresholds were defined based on FMO controls (see ). (D) Flow-cytometry quantification of marker-positive cells in TC-hMDMs and TC-BMDMs. (E) ELISA of IL-10, TGF-β, and iNOS in culture supernatants. (F) CCK-8 assays of A549 and LLC cells. (G) Colony-formation assays of A549 and LLC cells with quantification. (H) Bioluminescence-based growth readouts of patient-derived LUAD organoids (PDO #1 and PDO #2) after co-culture with TC-hMDMs. (I) Immunoblot analysis of EMT-related proteins (E-cadherin, N-cadherin, Vimentin) in A549 and LLC cells. (J) Transwell migration and invasion assays of A549 and LLC cells with quantification. Scale bar, 50 μm. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001; ns, not significant.

Journal: Non-coding RNA Research

Article Title: CircSMAD4 shapes matrix-remodeling TAMs in lung adenocarcinoma

doi: 10.1016/j.ncrna.2026.03.003

Figure Lengend Snippet: circSMAD4 drives tumor-educated M2-like polarization of macrophages and promotes tumor-cell aggressiveness. (A) Workflow for generating TC-hMDMs and TC-BMDMs, circSMAD4 knockdown, and downstream functional assays. (B) RT–qPCR analysis of M1-associated markers (MHC-II [HLA-DRA in TC-hMDMs; H2-Ab1 in TC-BMDMs], NOS2, and CD86) and M2-associated markers (CD163, CD206, and ARG1) in TC-hMDMs and TC-BMDMs. (C) Representative flow-cytometry histograms for HLA-DR, iNOS, CD86, CD163, CD206, and ARG1 in TC-hMDMs. Gating strategy and marker thresholds were defined based on FMO controls (see ). (D) Flow-cytometry quantification of marker-positive cells in TC-hMDMs and TC-BMDMs. (E) ELISA of IL-10, TGF-β, and iNOS in culture supernatants. (F) CCK-8 assays of A549 and LLC cells. (G) Colony-formation assays of A549 and LLC cells with quantification. (H) Bioluminescence-based growth readouts of patient-derived LUAD organoids (PDO #1 and PDO #2) after co-culture with TC-hMDMs. (I) Immunoblot analysis of EMT-related proteins (E-cadherin, N-cadherin, Vimentin) in A549 and LLC cells. (J) Transwell migration and invasion assays of A549 and LLC cells with quantification. Scale bar, 50 μm. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001; ns, not significant.

Article Snippet: For mouse experiments, mouse IL-10 was measured using the Mouse IL-10 ELISA Kit (R&D Systems, Cat# M1000B), and mouse TGF-β1 was measured using the Mouse TGF beta-1 ELISA Kit (Invitrogen, Cat# BMS608-4), following the manufacturers’ instructions.

Techniques: Knockdown, Functional Assay, Quantitative RT-PCR, Flow Cytometry, Marker, Enzyme-linked Immunosorbent Assay, CCK-8 Assay, Derivative Assay, Co-Culture Assay, Western Blot, Migration

Angiogenesis and collagen deposition in diabetic wound tissues following HPSL@SG hydrogel treatment. (A) Dihydroethidium (DHE) immunofluorescence staining and (B) semi-quantitative analysis of wound tissues from each treatment group on day 7, scale bar = 100 μm. Immunofluorescence staining of (C) MMP-9, IL-6, and IL-10, and (D) CD31, VEGF-A, and collagen I in wound tissue sections from each treatment group on day 7, scale bar = 100 μm. (E-J) Mean relative fluorescence intensity of each indicator in wound tissue sections from each treatment group on day 7, scale bar = 100 μm. All data are shown as mean ± SEM (n = 6).

Journal: Bioactive Materials

Article Title: Glucose/ROS-responsive and redox-gated adaptive hydrogel dressing for accelerating diabetic wound repair via synergistic cGAS/STING pathway inhibition and oxidative stress alleviation

doi: 10.1016/j.bioactmat.2026.03.025

Figure Lengend Snippet: Angiogenesis and collagen deposition in diabetic wound tissues following HPSL@SG hydrogel treatment. (A) Dihydroethidium (DHE) immunofluorescence staining and (B) semi-quantitative analysis of wound tissues from each treatment group on day 7, scale bar = 100 μm. Immunofluorescence staining of (C) MMP-9, IL-6, and IL-10, and (D) CD31, VEGF-A, and collagen I in wound tissue sections from each treatment group on day 7, scale bar = 100 μm. (E-J) Mean relative fluorescence intensity of each indicator in wound tissue sections from each treatment group on day 7, scale bar = 100 μm. All data are shown as mean ± SEM (n = 6).

Article Snippet: IL-6 and IL-10-specific antibodies were purchased from Bosterbio (Wuhan, China).

Techniques: Immunofluorescence, Staining, Fluorescence

Elevated PD-1 expression and altered cytokine levels in plasma of IE patients. (A) PD-1 expression on CD4 + CD25 high Tregs is significantly increased in IE patients, particularly in the ISE subgroup, while CD4 + and CD4 + CD25 + T cell percentages are reduced. (B) Plasma concentrations of IL-10 and IL-6 are elevated in IE patients, with IL-10 showing a progressive increase with seizure severity. (C) Correlation analyses reveal associations between immune parameters and clinical characteristics. ∗∗∗P < 0.001, ∗∗ P < 0.01, ∗ P < 0.05; ns indicates not significant.

Journal: Brain, Behavior, & Immunity - Health

Article Title: Exploring the role of PD-1 as a marker in drug-refractory epilepsy and its potential indication for valproic acid treatment

doi: 10.1016/j.bbih.2026.101238

Figure Lengend Snippet: Elevated PD-1 expression and altered cytokine levels in plasma of IE patients. (A) PD-1 expression on CD4 + CD25 high Tregs is significantly increased in IE patients, particularly in the ISE subgroup, while CD4 + and CD4 + CD25 + T cell percentages are reduced. (B) Plasma concentrations of IL-10 and IL-6 are elevated in IE patients, with IL-10 showing a progressive increase with seizure severity. (C) Correlation analyses reveal associations between immune parameters and clinical characteristics. ∗∗∗P < 0.001, ∗∗ P < 0.01, ∗ P < 0.05; ns indicates not significant.

Article Snippet: Concentrations of IL-10 and IL-6 in plasma and CSF were quantified using commercial double-antibody sandwich ELISA kits (Boster Bioengineering, China), according to the manufacturer's instructions.

Techniques: Expressing, Clinical Proteomics

Central nervous system immune activation in ISE patients. (A) PD-1 + CD4 + CD25 high Treg cell counts are significantly elevated in the CSF of ISE patients compared to controls. (B) Both IL-10 and IL-6 concentrations are increased in the CSF of ISE patients. (C) Age correlates positively with PD-1 + CD4 + CD25 low and CD4 + CD25 high Treg percentages, and negatively with CD4 + T cell percentage in the CSF of ISE patients. ∗∗∗P < 0.001, ∗∗P < 0.01, ∗P < 0.05.

Journal: Brain, Behavior, & Immunity - Health

Article Title: Exploring the role of PD-1 as a marker in drug-refractory epilepsy and its potential indication for valproic acid treatment

doi: 10.1016/j.bbih.2026.101238

Figure Lengend Snippet: Central nervous system immune activation in ISE patients. (A) PD-1 + CD4 + CD25 high Treg cell counts are significantly elevated in the CSF of ISE patients compared to controls. (B) Both IL-10 and IL-6 concentrations are increased in the CSF of ISE patients. (C) Age correlates positively with PD-1 + CD4 + CD25 low and CD4 + CD25 high Treg percentages, and negatively with CD4 + T cell percentage in the CSF of ISE patients. ∗∗∗P < 0.001, ∗∗P < 0.01, ∗P < 0.05.

Article Snippet: Concentrations of IL-10 and IL-6 in plasma and CSF were quantified using commercial double-antibody sandwich ELISA kits (Boster Bioengineering, China), according to the manufacturer's instructions.

Techniques: Activation Assay

VPA treatment modulates PD-1 expression and IL-10 levels independently of drug concentration. (A) Plasma PD-1 expression on both CD4 + CD25 high and CD4 + CD25 low Treg subsets decreases significantly after 48 h of VPA treatment. (B) Plasma IL-10 levels decrease significantly after VPA treatment, while IL-6 shows no significant change. (C) Seizure control time correlates with immunological parameters but not with VPA concentrations. (D) VPA concentrations in CSF are significantly lower than in plasma, with no change between d0 and d3, and no correlation with seizure control time. ∗∗∗P < 0.001, ∗∗P < 0.01, ∗P < 0.05; ns indicates not significant.

Journal: Brain, Behavior, & Immunity - Health

Article Title: Exploring the role of PD-1 as a marker in drug-refractory epilepsy and its potential indication for valproic acid treatment

doi: 10.1016/j.bbih.2026.101238

Figure Lengend Snippet: VPA treatment modulates PD-1 expression and IL-10 levels independently of drug concentration. (A) Plasma PD-1 expression on both CD4 + CD25 high and CD4 + CD25 low Treg subsets decreases significantly after 48 h of VPA treatment. (B) Plasma IL-10 levels decrease significantly after VPA treatment, while IL-6 shows no significant change. (C) Seizure control time correlates with immunological parameters but not with VPA concentrations. (D) VPA concentrations in CSF are significantly lower than in plasma, with no change between d0 and d3, and no correlation with seizure control time. ∗∗∗P < 0.001, ∗∗P < 0.01, ∗P < 0.05; ns indicates not significant.

Article Snippet: Concentrations of IL-10 and IL-6 in plasma and CSF were quantified using commercial double-antibody sandwich ELISA kits (Boster Bioengineering, China), according to the manufacturer's instructions.

Techniques: Expressing, Concentration Assay, Clinical Proteomics, Control

Genomic instability is observed in InCl 3 -treated TM3 cells. InCl 3 induces enlarged nuclei and micronuclei (as indicated by white arrowheads) in TM3 cells. (A) Nuclear shapes of CTL and InCl 3 -treated TM3 cells were analyzed using DAPI staining. The right panel represents enlarged views of selected regions. Micronuclei, small DAPI staining near the nucleus, are indicated by the arrowheads. Mitotic cells were identified and are marked with red circles. Scale bar, 10 µm. (B) Quantitative results of the nuclear area shown through DAPI staining. (C) Quantification of the proportions of cells with micronuclei [as indicated by selected regions 1 and 2 of (A), right panel]. (D) InCl 3 treatment did not affect the mitotic index. The proportions of mitotic cells (mitotic index) were quantified. (E) InCl 3 treatment reduced the levels of testosterone in the culture medium of TM3 cells. Quantitative results of relative testosterone levels measured through ELISA in the absence or presence of InCl 3 . InCl 3 treatment reduced steroidogenic gene expression. (F) Schematic diagram of testosterone production. Quantitative results of relative mRNA levels of (G) StAR, (H) HSD3B and (I) CYP11A1. Results are presented as mean ± SD from ≥3 independent experiments. *P<0.05, **P<0.01 and ***P<0.001. n.s., not significant; InCl 3 , indium chloride; StAR, steroidogenic acute regulatory protein; HSD3B, 3-β-hydroxy-δ-steroid dehydrogenase; CYP11A1, cytochrome P450 family 11 subfamily A member 1; E, enlarged nuclei; CTL, control.

Journal: Molecular Medicine Reports

Article Title: Indium (III) chloride inhibits testicular Leydig cell proliferation by disrupting centrosome copy numbers

doi: 10.3892/mmr.2026.13891

Figure Lengend Snippet: Genomic instability is observed in InCl 3 -treated TM3 cells. InCl 3 induces enlarged nuclei and micronuclei (as indicated by white arrowheads) in TM3 cells. (A) Nuclear shapes of CTL and InCl 3 -treated TM3 cells were analyzed using DAPI staining. The right panel represents enlarged views of selected regions. Micronuclei, small DAPI staining near the nucleus, are indicated by the arrowheads. Mitotic cells were identified and are marked with red circles. Scale bar, 10 µm. (B) Quantitative results of the nuclear area shown through DAPI staining. (C) Quantification of the proportions of cells with micronuclei [as indicated by selected regions 1 and 2 of (A), right panel]. (D) InCl 3 treatment did not affect the mitotic index. The proportions of mitotic cells (mitotic index) were quantified. (E) InCl 3 treatment reduced the levels of testosterone in the culture medium of TM3 cells. Quantitative results of relative testosterone levels measured through ELISA in the absence or presence of InCl 3 . InCl 3 treatment reduced steroidogenic gene expression. (F) Schematic diagram of testosterone production. Quantitative results of relative mRNA levels of (G) StAR, (H) HSD3B and (I) CYP11A1. Results are presented as mean ± SD from ≥3 independent experiments. *P<0.05, **P<0.01 and ***P<0.001. n.s., not significant; InCl 3 , indium chloride; StAR, steroidogenic acute regulatory protein; HSD3B, 3-β-hydroxy-δ-steroid dehydrogenase; CYP11A1, cytochrome P450 family 11 subfamily A member 1; E, enlarged nuclei; CTL, control.

Article Snippet: Mouse serum testosterone levels were quantified using a commercially available Mouse T Testosterone ELISA kit (cat. no. EM1850-HS; Wuhan Fine Biotech Co., Ltd.), according to the manufacturer's instructions.

Techniques: Staining, Enzyme-linked Immunosorbent Assay, Gene Expression, Control

Continuous intraosseous administration of SCS prevents glucocorticoid-induced bone degeneration. ( A ) Schematic illustration of the glucocorticoid (GC; MPS)-induced bone deterioration and intraosseous SCS treatment. ( B-D ) Representative H&E staining images of the femur at 6 weeks (B). Magnified views of the cortical bone and trabecular bone in the marrow cavity are shown on the right. Solid arrows indicate normal osteocytes, while hollow arrows indicate empty osteocyte lacunae. Quantification of empty lacunae ratios in cortical bone (C) and trabecular bone (D). n = 6 biological replicates. (Scale bars, 500 μm and 25 μm) ( E-H ) Representative immunofluorescence staining of OPN + mature osteoblasts, osteolectin + osteoprogenitors, and VE-cadherin + endothelial cells (ECs) in femur at 6 weeks (E), and corresponding quantifications (F–H). n = 6 biological replicates. (Scale bars, 100 μm and 20 μm) ( I and J ) Representative flow cytometry plots of capillary subtypes in the femur (I), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (J). n = 6 biological replicates. ( K and L ) Flow cytometry plots showing Sca-1 hi CD31 hi arteriolar ECs (K), and corresponding quantification (L). n = 6 biological replicates. ( M and N ) Representative micro-CT 3D images of the femur (M). Quantitative analysis of percent bone volume (BV/TV) (N). n = 6 biological replicates. (Scale bars, 1.5 mm, 600 μm and 545 μm) ( O and P ) ELISA analysis of VEGF (O) and PDGF-BB (P) levels in bone marrow supernatant and peripheral serum from PBS- and SCS-treated groups at week 6. n = 6 biological replicates. ( Q ) ELISA quantification of the osteogenic factor osteocalcin in peripheral serum at week 6. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, F, G, H, J, L, N, O, P and Q ).

Journal: Bioactive Materials

Article Title: Sulfated polysaccharide prevents senescent adipocyte-driven osteonecrosis by stem cell fate reprogramming

doi: 10.1016/j.bioactmat.2025.11.039

Figure Lengend Snippet: Continuous intraosseous administration of SCS prevents glucocorticoid-induced bone degeneration. ( A ) Schematic illustration of the glucocorticoid (GC; MPS)-induced bone deterioration and intraosseous SCS treatment. ( B-D ) Representative H&E staining images of the femur at 6 weeks (B). Magnified views of the cortical bone and trabecular bone in the marrow cavity are shown on the right. Solid arrows indicate normal osteocytes, while hollow arrows indicate empty osteocyte lacunae. Quantification of empty lacunae ratios in cortical bone (C) and trabecular bone (D). n = 6 biological replicates. (Scale bars, 500 μm and 25 μm) ( E-H ) Representative immunofluorescence staining of OPN + mature osteoblasts, osteolectin + osteoprogenitors, and VE-cadherin + endothelial cells (ECs) in femur at 6 weeks (E), and corresponding quantifications (F–H). n = 6 biological replicates. (Scale bars, 100 μm and 20 μm) ( I and J ) Representative flow cytometry plots of capillary subtypes in the femur (I), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (J). n = 6 biological replicates. ( K and L ) Flow cytometry plots showing Sca-1 hi CD31 hi arteriolar ECs (K), and corresponding quantification (L). n = 6 biological replicates. ( M and N ) Representative micro-CT 3D images of the femur (M). Quantitative analysis of percent bone volume (BV/TV) (N). n = 6 biological replicates. (Scale bars, 1.5 mm, 600 μm and 545 μm) ( O and P ) ELISA analysis of VEGF (O) and PDGF-BB (P) levels in bone marrow supernatant and peripheral serum from PBS- and SCS-treated groups at week 6. n = 6 biological replicates. ( Q ) ELISA quantification of the osteogenic factor osteocalcin in peripheral serum at week 6. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, F, G, H, J, L, N, O, P and Q ).

Article Snippet: Serum concentrations of the osteogenic marker osteocalcin (NOVUS, NBP2-68151) were also measured.

Techniques: Staining, Immunofluorescence, Flow Cytometry, Micro-CT, Enzyme-linked Immunosorbent Assay

SCS targets downstream senescent lineage commitment of bone marrow MSCs to mitigate GC-induced bone deterioration. ( A ) Schematic diagram illustrating the experimental design: CD45 − Ter119 − CD31 − LepR + MSCs isolated from mice co-treated with SCS and MPS for 7 days were subjected to in vitro lineage-competitive differentiation, followed by DEX-induced senescence in lineage-mixed cells. These cells were then adoptively transplanted into healthy bone marrow cavity to assess bone deterioration development. ( B ) Representative H&E-stained images of the femur 12 weeks after adoptive transfer. PBS-DEX group: LepR + MSCs from PBS and MPS co-treated mice subjected to in vitro lineage differentiation and DEX-induced senescence, followed by transplantation. SCS-DEX group: LepR + MSCs from SCS and MPS co-treated mice processed similarly. PBS group: solvent control without cell transplantation. Solid arrows indicate intact osteocytes; hollow arrows indicate empty lacunae. (Scale bars, 250 μm and 25 μm) ( C – E ) Quantitative analysis of marrow hypertrophic adipocyte diameter (C), proportion of empty osteocyte lacunae in trabecular bone (D), and adipocyte number (E) in the metaphysis 12 weeks post-transplantation. n = 19 biological replicates (C), n = 6 biological replicates (D), n = 8 biological replicates (E). ( F ) Quantification of empty lacunae in epiphysis at 12 weeks post-transplantation. n = 6 biological replicates. ( G – I ) Representative flow cytometry plots of capillary ECs subtypes in the femur at 12 weeks (G), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (H) and CD45 − Ter119 − CD31 lo Emcn lo ECs (I). n = 6 biological replicates. ( J and K ) Representative flow cytometry plots (J) and corresponding quantification (K) of CD45 − Ter119 − Sca-1 hi CD31 hi arteriolar ECs in the femur at 12 weeks post-transplantation. n = 6 biological replicates. ( L ) Representative micro-CT images of the femur at 12 weeks post-transplantation across different treatment groups. (Scale bars, 1.5 mm and 500 μm) ( M – P ) Quantitative analysis of bone parameters in the metaphysis: bone mineral density (BMD) (M), percent bone volume (BV/TV) (N), trabecular separation (Tb.Sp) (O), and trabecular number (Tb.N) (P). n = 6 biological replicates. ( Q ) Serum ELISA analysis of the osteogenic marker osteocalcin at 12 weeks post-transplantation. n = 6 biological replicates. ( R and S ) ELISA analysis of PDGF-BB (R) and VEGF (S) in both bone marrow supernatant and peripheral serum at 12 weeks post-transplantation. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, E, F, H, I, K, M, N, O, P, Q, R and S ).

Journal: Bioactive Materials

Article Title: Sulfated polysaccharide prevents senescent adipocyte-driven osteonecrosis by stem cell fate reprogramming

doi: 10.1016/j.bioactmat.2025.11.039

Figure Lengend Snippet: SCS targets downstream senescent lineage commitment of bone marrow MSCs to mitigate GC-induced bone deterioration. ( A ) Schematic diagram illustrating the experimental design: CD45 − Ter119 − CD31 − LepR + MSCs isolated from mice co-treated with SCS and MPS for 7 days were subjected to in vitro lineage-competitive differentiation, followed by DEX-induced senescence in lineage-mixed cells. These cells were then adoptively transplanted into healthy bone marrow cavity to assess bone deterioration development. ( B ) Representative H&E-stained images of the femur 12 weeks after adoptive transfer. PBS-DEX group: LepR + MSCs from PBS and MPS co-treated mice subjected to in vitro lineage differentiation and DEX-induced senescence, followed by transplantation. SCS-DEX group: LepR + MSCs from SCS and MPS co-treated mice processed similarly. PBS group: solvent control without cell transplantation. Solid arrows indicate intact osteocytes; hollow arrows indicate empty lacunae. (Scale bars, 250 μm and 25 μm) ( C – E ) Quantitative analysis of marrow hypertrophic adipocyte diameter (C), proportion of empty osteocyte lacunae in trabecular bone (D), and adipocyte number (E) in the metaphysis 12 weeks post-transplantation. n = 19 biological replicates (C), n = 6 biological replicates (D), n = 8 biological replicates (E). ( F ) Quantification of empty lacunae in epiphysis at 12 weeks post-transplantation. n = 6 biological replicates. ( G – I ) Representative flow cytometry plots of capillary ECs subtypes in the femur at 12 weeks (G), with quantification of CD45 − Ter119 − CD31 hi Emcn hi ECs (H) and CD45 − Ter119 − CD31 lo Emcn lo ECs (I). n = 6 biological replicates. ( J and K ) Representative flow cytometry plots (J) and corresponding quantification (K) of CD45 − Ter119 − Sca-1 hi CD31 hi arteriolar ECs in the femur at 12 weeks post-transplantation. n = 6 biological replicates. ( L ) Representative micro-CT images of the femur at 12 weeks post-transplantation across different treatment groups. (Scale bars, 1.5 mm and 500 μm) ( M – P ) Quantitative analysis of bone parameters in the metaphysis: bone mineral density (BMD) (M), percent bone volume (BV/TV) (N), trabecular separation (Tb.Sp) (O), and trabecular number (Tb.N) (P). n = 6 biological replicates. ( Q ) Serum ELISA analysis of the osteogenic marker osteocalcin at 12 weeks post-transplantation. n = 6 biological replicates. ( R and S ) ELISA analysis of PDGF-BB (R) and VEGF (S) in both bone marrow supernatant and peripheral serum at 12 weeks post-transplantation. n = 6 biological replicates. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant. Statistical significance was determined using one-way ANOVA with Tukey's post hoc test ( C, D, E, F, H, I, K, M, N, O, P, Q, R and S ).

Article Snippet: Serum concentrations of the osteogenic marker osteocalcin (NOVUS, NBP2-68151) were also measured.

Techniques: Isolation, In Vitro, Staining, Adoptive Transfer Assay, Transplantation Assay, Solvent, Control, Flow Cytometry, Micro-CT, Enzyme-linked Immunosorbent Assay, Marker

Effects of CuONPs on allergic inflammation and oxidative stress in OVA-induced asthmatic mice. (A) Airway hyperresponsiveness assessed as total respiratory system resistance in response to methacholine challenge (10, 20, and 40 mg/mL). (B–F) Total and differential inflammatory cell counts in BALF. (G–L) IL-1β, IL-6, TNF-α, IL-4, IL-5, and IL-13 levels in BALF, measured by ELISA. (M and N) Total IgE and OVA specific IgE levels in serum. (O and P) MDA levels and SOD activity in lung tissue. Data are presented as means ± SD (n = 6 mice/group). ∗∗ p < 0.01 and ∗∗∗ p < 0.001 versus NC group. # p < 0.05, ## p < 0.01, and ### p < 0.001 versus OVA group.

Journal: Redox Biology

Article Title: Nrf2 pathway mediates copper oxide nanoparticle-induced exacerbation of allergic asthma

doi: 10.1016/j.redox.2026.104180

Figure Lengend Snippet: Effects of CuONPs on allergic inflammation and oxidative stress in OVA-induced asthmatic mice. (A) Airway hyperresponsiveness assessed as total respiratory system resistance in response to methacholine challenge (10, 20, and 40 mg/mL). (B–F) Total and differential inflammatory cell counts in BALF. (G–L) IL-1β, IL-6, TNF-α, IL-4, IL-5, and IL-13 levels in BALF, measured by ELISA. (M and N) Total IgE and OVA specific IgE levels in serum. (O and P) MDA levels and SOD activity in lung tissue. Data are presented as means ± SD (n = 6 mice/group). ∗∗ p < 0.01 and ∗∗∗ p < 0.001 versus NC group. # p < 0.05, ## p < 0.01, and ### p < 0.001 versus OVA group.

Article Snippet: BALF was centrifuged at 300× g for 10 min at 4 °C, and the supernatant was stored for cytokine analysis using commercially available enzyme-linked immunosorbent assay (ELISA) kits to quantify IL-1β, IL-6, tumor necrosis factor (TNF)-α, IL-4, IL-5, and IL-13 (R&D Systems, Minneapolis, MN, USA; Cat. No. MLB00C, M6000B, MTA00B, M4000B, M5000, and M1300CB, respectively).

Techniques: Enzyme-linked Immunosorbent Assay, Activity Assay

Effects of Nrf2 overexpression on allergic inflammation and oxidative stress in CuONP-exposed asthmatic mice. (A) Immunofluorescence analysis of lung tissue from mice administered PBS or AAV2/8-GFP via intratracheal instillation. (B) Airway hyperresponsiveness assessed as total respiratory system resistance in response to methacholine challenge (10, 20, and 40 mg/mL). (C–G) Total and differential inflammatory cell counts in BALF. (H–M) IL-1β, IL-6, TNF-α, IL-4, IL-5, and IL-13 levels in BALF, measured by ELISA. (N and O) Total IgE and OVA specific IgE levels in serum. (P and Q) MDA levels and SOD activity in lung tissue. Data are presented as means ± SD (n = 3 mice/group for panels A; n = 6 mice/group for panels B–Q). In panel B, ## p < 0.01 indicates significant differences between GFP-NC and GFP-OVA, and ∗∗ p < 0.01 indicates significant differences between GFP-OVA + CuONPs and Nrf2-OVA + CuONPs. For panels C–Q, ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001 indicate significant differences between AAV-GFP and AAV-Nrf2 within each condition.

Journal: Redox Biology

Article Title: Nrf2 pathway mediates copper oxide nanoparticle-induced exacerbation of allergic asthma

doi: 10.1016/j.redox.2026.104180

Figure Lengend Snippet: Effects of Nrf2 overexpression on allergic inflammation and oxidative stress in CuONP-exposed asthmatic mice. (A) Immunofluorescence analysis of lung tissue from mice administered PBS or AAV2/8-GFP via intratracheal instillation. (B) Airway hyperresponsiveness assessed as total respiratory system resistance in response to methacholine challenge (10, 20, and 40 mg/mL). (C–G) Total and differential inflammatory cell counts in BALF. (H–M) IL-1β, IL-6, TNF-α, IL-4, IL-5, and IL-13 levels in BALF, measured by ELISA. (N and O) Total IgE and OVA specific IgE levels in serum. (P and Q) MDA levels and SOD activity in lung tissue. Data are presented as means ± SD (n = 3 mice/group for panels A; n = 6 mice/group for panels B–Q). In panel B, ## p < 0.01 indicates significant differences between GFP-NC and GFP-OVA, and ∗∗ p < 0.01 indicates significant differences between GFP-OVA + CuONPs and Nrf2-OVA + CuONPs. For panels C–Q, ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001 indicate significant differences between AAV-GFP and AAV-Nrf2 within each condition.

Article Snippet: BALF was centrifuged at 300× g for 10 min at 4 °C, and the supernatant was stored for cytokine analysis using commercially available enzyme-linked immunosorbent assay (ELISA) kits to quantify IL-1β, IL-6, tumor necrosis factor (TNF)-α, IL-4, IL-5, and IL-13 (R&D Systems, Minneapolis, MN, USA; Cat. No. MLB00C, M6000B, MTA00B, M4000B, M5000, and M1300CB, respectively).

Techniques: Over Expression, Immunofluorescence, Enzyme-linked Immunosorbent Assay, Activity Assay